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Semaphorins are a large family of molecules involved in axonal guidance during the
development of the nervous system and have been recently shown to have both
angiogenic and anti-angiogenic properties. Specifically, semaphorin 7A (SEMA7A) has
been reported to have a chemotactic activity in neurogenesis and to be an immune
modulator through α1β1integrins. SEMA7A has been shown to promote monocyte
chemotaxis and induce them to produce proinflammatory mediators. In this study we
explored the role of SEMA7A in a murine model of breast cancer. We show that SEMA7A
is highly expressed by DA-3 murine mammary tumor cells in comparison to normal
mammary cells (EpH4), and that peritoneal elicited macrophages from mammary tumor-
bearing mice also express SEMA7A at higher levels compared to those derived from
normal mice. We also show that murine macrophages treated with recombinant murine
SEMA7A significantly increased their expression of proangiogenic molecule CXCL2/MIP-
2. Gene silencing of SEMA7A in peritoneal elicited macrophages from DA-3 tumor-bearing
mice resulted in decreased CXCL2/MIP-2 expression. Mice implanted with SEMA7A
silenced tumor cells showed decreased angiogenesis in the tumors compared to the wild
type tumors. Furthermore, peritoneal elicited macrophages from mice bearing SEMA7A-
silenced tumors produce significantly (p < 0.01) lower levels of angiogenic proteins, such
as CXCL2/MIP-2, CXCL1, and MMP-9, compared to those from control DA-3 mammary
tumors. We postulate that SEMA7A in mammary carcinomas may skew monocytes into a
pro-tumorigenic phenotype to support tumor growth. SEMA7A could prove to be valuable
in establishing new research avenues toward unraveling important tumor-host immune
interactions in breast cancer patients.
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INTRODUCTION
Semaphorins (SEMAs) comprise a large family of transmem-
brane and secreted proteins that have been described as axon
guidance molecules during neuronal development (Koppel et al.,
1997; Pasterkamp and Kolodkin, 2003; Kikutani et al., 2007).
Semaphorins, grouped into eight classes, are characterized by the
presence of a conserved large SEMA domain (∼500 amino acids)
at the N-terminal domain and differentiated by their C-terminus
(Koppel et al., 1997). Of the 8 classes of semaphorins, classes
1 and 2 are mostly found in invertebrates while classes 3–7 are
found in vertebrates and the viral (V) class encoded by viruses.
Emerging evidence is revealing additional roles for semaphorins
in the immune system where they seem to exert diverse effects
on leukocyte migration, adhesion, and inflammatory responses
(Kikutani et al., 2007; Sakurai et al., 2010).
A growing body of evidence demonstrates the participation
of classical neuronal developmental molecules in either tumor
growth or inhibition by their effects on angiogenesis (Banu et al.,
2006; Basile et al., 2006; Guttmann-Raviv et al., 2007; Acevedo
et al., 2008; Sierra et al., 2008; Casazza et al., 2011). Semaphorins
have been found to affect tumor progression by either mod-
ulating tumor angiogenesis, recruiting bone marrow cells that
could then influence tumor progression, or by directly affect-
ing the behavior of tumor cells. While some semaphorins were
found to inhibit angiogenesis, others enhanced new blood ves-
sel growth. Proangiogenic semaphorins include semaphorin 4A
(SEMA4A), semaphorin 4D (SEMA4D), and semaphorin 5A
(SEMA5A) (Capparuccia and Tamagnone, 2009). However, some
members in semaphorin 3 (SEMA3) class have antiangiogenic
effects (Basile et al., 2004; Varshavsky et al., 2008; Sadanandam
et al., 2010; Sakurai et al., 2010;Meda et al., 2012). Althoughmany
classes of semaphorins have been studied in different cancers, the
role of sempahorin7A (SEMA7A) in cancer progression is largely
unknown. SEMA7A is a novel transmembrane GPI-anchored
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protein that has been described to function through plexin C1 and
beta-integrins in multiple systems (Zhou et al., 2008). Recently,
SEMA7A has been reported to be one of the proteins secreted
by glioblastoma tumor cells that contribute to the highly inva-
sive phenotype (Formolo et al., 2011). In this study we explore
the role of SEMA7A in breast cancer progression using the
DA-3 mammary tumor model. Specifically, we are investigating
how SEMA7A can affect macrophage production of angiogenic
molecules.
There is scarce information in literature on how SEMA7A
affects macrophage induced angiogenesis. An angiogenic role
for SEMA7A has been recently described to mediate vascu-
lar growth by bFGF stimulated fibroblasts in an experimental
model of corneal neovascularization (Ghanem et al., 2011). In
this manuscript using peritoneal elicited macrophages, a rich
source of peripheral macrophages, we describe that SEMA7A
induces macrophages to produce angiogenic molecules such as
CXCL2/MIP-2 and that silencing the SEMA7A gene results in
decreased production of these growth promoting molecules.
MATERIALS AND METHODS
MICE AND CELL LINES
Female BALB/c mice were used in all studies (Charles River
Laboratories, 8–12 week-olds), and were housed and used accord-
ing to the National Institutes of Health guidelines, under proto-
cols approved by Florida Atlantic University Institutional Animal
Care and Use Committee. In these studies, we used the DA-
3 cell line which was derived from the D1-DMBA-3 mam-
mary tumor syngeneic to BALB/c mice and were provided by
Dr. Diana M. Lopez, University of Miami School of Medicine,
Miami, FL (Sotomayor et al., 1991). EpH4 mammary cells, a nor-
mal mammary cell line, were provided by Dr. Jenifer Prosperi,
Indiana University School of Medicine-South Bend, IN. Both
DA-3 and EpH4 cells were grown in complete DMEM media
(DMEM with 10% FBS). RAW 264.7 cells (American Type
Culture Collection, Manassas, VA, USA) were grown and main-
tained in RPMI 1640 containing 5% FBS as described previ-
ously (Nishiyama et al., 2006, 2008). Female BALB/c mice were
inoculated in the lower right ventral quadrant with 7.5 × 105
mammary tumor cells of the following types: (1) DA-3 cells
silenced for the SEMA7A gene, (2) DA-3 cells with scramble
shRNA, or (3) wild-type DA-3 cells. Imaging studies and caliper
measurements of the primary tumors were performed up to 3
weeks post-tumor cell implantation and discontinued after this
time point since the tumors become necrotic and fall off after
3 weeks. Tissues from 5-week tumor bearers were used in most
of the studies, unless specified, based on our previous stud-
ies that production of tumor-derived factors peak at this time
point (Lopez et al., 1991). At 5 weeks, tumors are not observed
in the lung, liver, and bone. The establishment of metastas-
tic colonies at distant sites occur at 10–12 weeks if 500–750 ×
103 cells are inoculated. For determination of angiogenesis by
AngioSense (PerkinElmer, Waltham, MA), mice were implanted
with SEMA7A shRNA silencedmammary tumor cells or scramble
shRNA control mammary tumor cells and imaged at 21 days
post-tumor implantation while tissues were collected at 5 weeks
post-tumor cell implantation.
CELL CULTURES
To obtain peritoneal elicited macrophages (PEMs), mice were
injected intraperitoneally with 1.5mL of 3% thioglycollate and
4 days post-thioglycollate injection and the peritoneal exudate
cells were collected by peritoneal lavage with ice-cold RPMI
1640 with 10% fetal bovine serum. It is well-established that
the optimal time point for harvesting PEMs is 4 days post-
thioglycollate injection (Zhang et al., 2008). As our previous
studies have shown increased chemokine and MMP-9 expression
at 4–5 weeks post tumor cell inoculation, we chose 5 week time
point to assess the role of SEMA7A in inducing proangiogenic
factors by macrophages (Owen et al., 2003, 2011). PEMs from
normal (N-PEM) and DA-3 tumor-bearing (DA-3 PEM) mice
were then purified using CD11b magnetic beads (Miltenyi Biotec
Inc., Auburn, CA). 2 × 106 cells/mL were preconditioned by cul-
turing with rmSEMA7A (5μg/mL) (R&D Systems, Minneapolis,
MN) and incubated for 24 h followed by stimulation with
LPS (500 ng/mL) (Sigma Aldrich, St.Louis, MO) for an addi-
tional 12 h for RNA and 18 h for protein collection. RAW 264.7
macrophages were also conditioned as described above. For cell
signaling inhibition studies, RAW 264.7 cells were pretreated with
1μM MAPK inhibitor, U0126 (Calbiochem, inhibitors, EMD
Millipore, Billerica, MA) for 1 h, conditioned with rmSEMA7A
for 12 h and then stimulated with LPS (500 ng/mL) for an addi-
tional 12 h.
IMMUNOFLUORESCENCE
To determine the expression of SEMA7A, DA-3 mammary tumor
cells were plated onto a confocal cover slide, post-fixed in
4% paraformaldehyde, blocked in 4% BSA and labeled with
0.1μg/mL rat anti-SEMA7A (R&D Systems) followed by incu-
bation in secondary antibody using donkey anti-rat IgG con-
jugated to AlexaFluor 488 (Molecular Probes, Eugene, OR).
To visualize nuclei, DAPI (Vector Laboratories, Burlingame,
CA) was added, cover-slipped with Vectashield and exam-
ined by confocal microscopy (Carl Zeiss Microimaging, Inc.,
Thornwood, NY).
RNA ISOLATION AND REAL-TIME REVERSE
TRANSCRIPTASE-POLYMERASE CHAIN REACTION
Total RNA was extracted from murine tumor cells, RAW
264.7 macrophages or peritoneal elicited macrophages using
the RNeasy Protect Mini Kit (QIAGEN) according to man-
ufacturer’s instructions. Briefly, cDNA was synthesized using
Quantitech Reverse Transcription Kit (Qiagen, Valencia, CA) and
gene expression was detected by SYBR Green real-time PCR anal-
ysis using SYBR RT²qPCR primers (Qiagen, proprietary primers,
sequence not disclosed). The mRNA levels of gene of interest
were normalized to β-actin mRNA levels. PCR cycles followed the
sequence: 10min at 95◦C of initial denaturation; 15 s at 95◦C; and
40 cycles of 1min each at 60◦C for annealing. The samples were
amplified using the Strategene MX3005P cycler.
FLOW CYTOMETRY STUDIES
The expression of CD11b and CD29 onmacrophages was assessed
by flow cytometry (FACS-Calibur, BD Biosciences, San Jose,
CA). N-PEMs and DA-3 PEMs were stained by incubating with
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FITC-CD29 (0.125μg/106 cells) and APC-CD11b (0.1μg /106
cells) (both from BioLegend, San Diego, CA) for 20min at 4◦C.
Surface expression was assessed by counting 10,000 cells and
analyzed by FloJo software (Tree Star, Inc., Ashland, OR).
SILENCING OF SEMA7A IN MACROPHAGES
SEMA7A gene silencing in DA-3 PEMs was achieved by RNA
interference via short hairpin RNA (Origene, Rockville, MD)
as described above. Briefly, PT-67 packaging cells were trans-
fected with one of the following plasmids: (1) plasmid encoding
for shRNA sequence specifically for the SEMA7A gene and (2)
scramble shRNA plasmid not specific for the SEMA7A gene,
using Lipofectamine 2000 according to manufacturer’s protocol.
0.45μm filtered PT-67 transfected supernatants containing the
retrovirus were used to silence SEMA7A gene in DA-3 PEMs for
36 h. Macrophages were then stimulated with LPS (100 ng/ml)
for 12 h and q-PCR was performed to confirm SEMA7A gene
silencing.
SILENCING OF SEMA7A IN DA-3 MURINE MAMMARY TUMOR CELLS
Semaphorin 7A gene silencing in DA-3 mammary tumor cells
was achieved using RNA interference via short hairpin RNA
(Origene). A retrovirus shRNA plasmid system was used for
stable SEMA7A gene knockdown. To generate the retrovirus
infecting particles, PT-67 packaging cells were transfected with
one of the following plasmids: (1) plasmid encoding for shRNA
sequence specifically for the SEMA7A gene and (2) scramble
shRNA plasmid not specific to the SEMA7A gene. Transfection
was performed using standard Lipofectamine 2000 according
to manufacturer’s protocol. The different variants of trans-
fected PT-67 cells were selected for 2 weeks with puromycin
(2μg/mL) and the cell-free/retrovirus-rich supernatants from
the different PT-67 variants and controls were used to infect
DA-3 cells for 24–48 h. The different DA-3 variants were then
selected with puromycin (1μg/mL) for 4 weeks. To confirm
gene knockdown, real time quantitative polymerase chain reac-
tion (q-PCR) (Qiagen) was performed using the SEMA7A
specific primers according to manufacturer’s protocol. Cells
were passaged and selected until at least a 5-fold decrease
in the SEMA7A gene expression was achieved when com-
pared to the scramble control. The results of gene expres-
sion were then confirmed by western blotting for the SEMA7A
protein.
MONOCYTE MIGRATION ASSAY
To test migration, RAW 264.7 murine monocytes were labeled
with Calcein-AM (10μM) and used in a modified Boyden
Chamber assay. Briefly, 105 RAW264.7 were placed in the tran-
swell insert (8μM pores) (BD Biosciences) of the upper chamber
with lower chamber containing supernatants from: (1) DA-3 cells
silenced for the SEMA7A gene, (2) DA-3 cells with scramble
shRNA, and (3) wild-type DA-3 cells and incubated at 37◦C in
a CO2 incubator for 12 h. RAW 264.7 macrophage migration was
measured using a plate reader set at an excitation wavelength of
∼485 nm and an emission wavelength of ∼520 nm. Absorbance
values among the various groups were measured at least 2 times
in triplicate and fitted to a 7-point standard curve.
PROTEIN DETERMINATION
DA-3 murine mammary tumor cells were cultured under opti-
mal conditions using DMEM culture media with 10% FBS
until ∼80% confluency was achieved. DA-3 tumor cells and DA-
3 SEMA7A-silenced cells or intraperitoneal macrophages from
5-week DA-3 mammary tumor-bearing mice were lysed with
sample buffer (20mM dithiothreitol, 6% SDS, 0.25M Tris, pH
6.8, 10% glycerol, 10mM NaF and bromophenyl blue) and used
to extract total protein. 20μg of total protein from DA-3 cells and
PEMs were resolved on 4–20% Mini-Protean SDS-PAGE gradi-
ent gels (BioRad Life Sciences, Hercules, CA) and transferred to
PVDF membrane (Pierce, Rockford, IL) using a semi-dry trans-
fer transblotter (BioRad) at 20Volts for 40min. The membrane
was blocked overnight at 4◦C in SeaBlock (Calbiochem), and
subsequently incubated at room temperature with anti-mouse
SEMA7A monoclonal antibody (1μg/ml) (R&D Systems) and
anti-mouse beta actin polyclonal antibody (0.25μg/ml) (Li-Cor
Biosciences, Lincoln, NE). Western blots were washed for 10min
three times with 0.5% Tween-PBS followed by 1 h incubation
at room temperature with corresponding fluorescent antibodies
(Li-Cor Biosciences). Blots were washed again for 10min three
times with 0.5% Tween-PBS and then dried at 37◦C for 20min.
The membranes were then were visualized with Li-Cor imager.
Protein concentration was normalized to beta-actin as loading
control.
ELISAs of CXCL1, CXCL2/MIP-2 and MMP-9 (R&D Systems)
were performed following manufacturer suggested protocol from
DA-3 tumor control mice.
IMMUNOHISTOCHEMISTRY
Formalin-fixed tissue from controls, SEMA7A scramble controls
and SEMA7A silenced tumors was paraffin embedded and sec-
tioned at 4-micron thickness. Pre-treatment of formalin-fixed,
paraffin-embedded tissue sections with heat-induced epitope
retrieval (HIER) was done using diluted EnVision™ FLEX Target
Retrieval Solution, High pH (50×) (Dako Omnis, Carpinteria,
CA) following manufacturer protocol. The sections were deparaf-
finized and stained with hematoxylin and eosin (H&E) with auto-
mated Tissue Tek® 2000 processor (Sakura-Finetek, Torrance,
CA). Adjacent tumor sections were assessed for vascularity using
CD31 antibody. Dako FLEX monoclonal mouse anti-human
CD31 antibody (diluted 1:30, DAKO) was used to highlight the
vasculature of the tumors. CD31, expressed almost exclusively on
endothelial cells, is a brown antibody stain against a hematoxylin
counter stain. Photographs were taken at 50× magnification
with mineral oil immersion using Olympus MDOB3 microscope
and photographed with OlympusDP21 digital camera (Center
Valley, PA).
TUMOR MEASUREMENTS AND IN VIVO IMAGING FOR ANGIOGENESIS
Tumor size determination was performed by measuring the two
longest perpendicular axes in the x/y plane of the tumor nearest
to 0.1mm by caliper measurement. The depth was assumed to
be equivalent to the shortest of the perpendicular axes, defined
as y and tumor volume = x(y)2/2. To account for vasculariza-
tion in mice injected with either wild type DA-3 tumor cells
or those silenced for SEMA7A, near infrared blood pool agent
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AngioSense 680 probe (2 nmol/mouse in 150μL volume) (Perkin
Elmer, Waltham, MA) was injected via tail vein 24 h before imag-
ing. Mice were imaged using a bioluminescence optical imager
(IVIS Lumina LTE, Perkin Elmer). Maximal near infrared sig-
nals were quantified using Living Image 2.5 (Xenogen, Perkin
Elmer) image analysis software. Infrared signals are reported as
photons/s.
Statistical analysis
Results are expressed as means ± standard deviation. Statistical
analyses were performed using GraphPad Prism 3 software
(LaJolla, CA). Statistical comparisons of paired groups were
determined by Student’s t-tests. Values of p < 0.05 were consid-
ered statistically significant.
RESULTS
SEMA7A IS EXPRESSED IN DA-3 MAMMARY TUMOR CELLS AND
EXPRESSION IS INCREASED IN PERITONEAL ELICITED MACROPHAGES
OF DA-3 MAMMARY TUMOR-BEARING MICE
Semaphorins have been described to be expressed by various
cell types. Although it is known that SEMA7A is expressed
by monocytes, activated T cells, and keratinocytes, it is not
known if tumor cells express SEMA7A. We therefore cultured
DA-3 mammary tumor cells and assessed for SEMA7A expres-
sion. Confocal image shows that SEMA7A is expressed by the
DA-3 mammary tumor cell line (Figure 1A). We then asked if
SEMA7A is expressed by EpH4 mammary cells, a normal mam-
mary cell line, and how do these levels compare with those in
DA-3 tumor cells? qPCR revealed very low levels of SEMA7A
expression in EpH4 cells compared to DA-3 mammary tumor
cells (Figure 1B).
Members of the semaphorin family have been reported to be
cleaved to generate soluble forms that have effects on immune
function (Kumanogoh and Kikutani, 2003). It was not known
if SEMA7A is solubilized in our tumor model. Since there are
no reliable ELISAs available to quantify secreted SEMA7A pro-
tein, dot blot analysis was used to determine if SEMA7A is
solubilized. Analysis of total protein from supernatants of 3 day
DA-3 mammary tumor cell cultures confirmed the soluble pro-
tein expression of SEMA7A, with increased levels reflected by
increased cell numbers (Figure 1C). It is possible that circu-
lating levels of cleaved SEMA7A could have effects on other
cells.
In the immune system, SEMA7A has been reported to be
expressed in the myeloid and the lymphoid lineage cells (Delorme
et al., 2005). There are no studies to date describing the expression
of SEMA7A in macrophages of mammary tumor bearers. Thus,
thioglycollate peritoneal elicited macrophages from normal (N-
PEMs) and DA-3 mammary tumor-bearing mice (DA-3 PEMs)
were therefore tested to determine SEMA7A expression. It is well-
established that the optimal time point for peritoneal elicited
macrophages is 4 days post-thioglycollate injection (Zhang et al.,
2008). At earlier time points (e.g., 4–24 h post-thioglycollate) the
majority of cells in the peritoneal cavity consist of neutrophils
(Melnicoff et al., 1989; Lam et al., 2013). SEMA7A expression
was determined at 3, 4, and 5 days post-thioglycollate injection
in normal and DA-3 mammary tumor-bearing mice. There were
no significant differences in SEMA7A expression at these days
in peritoneal elicited cells from either normal or tumor-bearing
mice. We therefore opted for 4 days as our set time point
for these studies. A 3-fold increase in SEMA7A expression at
the mRNA level was found in peritoneal elicited macrophages
from DA-3 PEMs (Figure 1D) compared to the expression in N-
PEMs. Similarly, increased protein expression of SEMA7A was
found in DA-3 PEMs compared to normal PEMs (Figure 1E).
Quantification of the bands from western blot analysis confirmed
increased SEMA7A protein expression in DA-3 PEMs.
EXPRESSION OF SEMA7A RECEPTOR, β1 INTEGRIN (CD29) IS
INCREASED IN DA-3 MAMMARY TUMOR CELLS AND MACROPHAGES
FROMMAMMARY TUMOR-BEARING MICE
The principal signaling function of SEMA7A in the nervous and
immune systems is mediated through α1β1 integrin (Pasterkamp
et al., 2003; Suzuki et al., 2007; Gan et al., 2011). Increased
β1 signaling has previously been shown to be associated with
decreased survival in invasive breast cancer (Yao et al., 2007). We
first determined if there is a differential β1 integrin expression in
EpH4 and DA-3 mammary tumor cells. Flow cytometric analysis
showed that even though the percentage of β1 integrin (CD29)
positive cells remained unchanged between the normal EpH4
cells and the DA-3 mammary tumor cells, the mean fluorescence
intensity was almost doubled in the tumor cells (Figure 2A).
The expression of SEMA7A’s receptor, β1 integrin, in peripheral
macrophages between normal and tumor bearers has not yet been
well characterized. We determined if there are altered levels of
β1 integrin expression in peritoneal elicited macrophages (PEMs)
from normal and DA-3 mammary tumor-bearing mice. PEMs
were gated based on the fluorescent intensity of CD11b expres-
sion (Figure 2B). Flow cytometric analysis of CD11blow PEMs
from normal and DA-3 tumor bearing mice revealed no signif-
icant differences in the frequency of CD29+ cells (Figure 2C).
In contrast, expression of CD11bhiCD29+ in DA-3 PEMs was
higher (p < 0.05) compared to the expression in normal PEMs
(Figure 2C).
TREATMENT OF MACROPHAGES WITH rmSEMA7A INDUCES
PRODUCTION OF ANGIOGENIC CXCL2/MIP-2
Macrophages from tumor-bearing mice are known to produce
angiogenic molecules (Mantovani et al., 1992). Previous stud-
ies have shown that tumor-derived factors induce macrophages
to produce angiogenic and proinflammatory molecules (Pollard,
2004). Holmes et al. have shown that SEMA7A induces the
production of proinflammatory molecules including the IL-8
homolog of chemokine CXCL2/MIP-2, which also has angio-
genic properties (Holmes et al., 2002). As shown in the pre-
vious section, DA-3 mammary tumor cells express and shed
SEMA7A. We therefore determined whether soluble SEMA7A
has an effect on macrophage function. Toward these stud-
ies we used the macrophage cell line RAW 264.7 in which
SEMA7A mRNA was undetectable (CT value > 37). RAW264.7
macrophages, as a model of tissue macrophages isolated from
normal mice, have been used frequently for in vitro studies of
macrophage function. qPCR analysis of RAW 264.7 macrophages
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FIGURE 1 | DA-3 mammary tumor cells express SEMA7A. (A) Shown
is the confocal images of DA-3 mammary tumor cells for SEMA7A
expression; (B) SEMA7A expression in EpH4 and DA-3 mammary tumor
cells as determined by qPCR; (C) DOT blot analysis of DA-3 mammary
tumor cell culture showing that SEMA7A is solubilized; (D) mRNA
expression of SEMA7A in peritoneal elicited macrophages (PEMs) from
normal and DA-3 mammary tumor-bearing mice; (E) Western blot analysis
of total protein from PEMs from control and DA-3 mammary tumor
bearers with 7 mice/group; also shown is integrated intensity graph of
western blot indicating higher levels of SEMA7A expression in tumor
bearers’ PEMs. In-vitro experiments are representative of three
independent experiments, ∗∗∗p ≤ 0.001.
preconditioned with rmSEMA7A revealed that expression of
proangiogenic molecules CXCL2/MIP-2 was increased by 5-
fold (p < 0.001) (Figure 3A) after LPS stimulation. We found
a significant (p < 0.01) increase in CXCL2/MIP-2 protein in
RAW 264.7 macrophages treated with rmSEMA7A and LPS
(Figure 3B). These studies also included culturing of RAW 264.7
cells with rmSEMA7A alone, which also showed an increase
in CXCL2/MIP-2 (data not shown). SEMA7A has previously
been reported to function through β1 integrin activation of
MAPK signaling pathway to promote monocyte inflammatory
response (Suzuki et al., 2007). To get insight if SEMA7A induces
CXCL2/MIP-2 viaMAPK pathway, RAW 264.7 macrophages were
pretreated with aMAPK inhibitor (U0126). We found that U0126
conditioned and rmSEMA7A treated cells exhibited decreased
(p < 0.01) production of CXCL2/MIP-2 compared to those cul-
tured with rmSEMA7A alone (Figure 3C).
To determine if freshly isolated macrophages from normal
and DA-3 mammary tumor bearers express CXCL2/MIP-2, peri-
toneal elicited macrophages from normal and DA-3 mammary
tumor bearers were obtained and assessed for CXCL2/MIP-2
expression by qPCR. A greater than 5-fold increase (p < 0.001)
in CXCL2/MIP-2 expression was observed in DA-3 PEMs com-
pared to normal PEMs (Figure 3D). We have previously shown
that tumor-derived factors have an effect on profile of PEMs
(Lopez et al., 1996; DiNapoli et al., 1997; Handel-Fernandez
et al., 1997; Torroella-Kouri et al., 2003). Therefore, peritoneal
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FIGURE 2 | β1 integrin expression is increased in DA-3 cells and
macrophages of mammary tumor-bearing mice. (A) Flow
cytometric analysis of DA-3 mammary tumor cells and EpH4
mammary epithelial cells for the expression of β1 integrin (CD29)
(a representative plot of 2 independent experiments); (B) scatter
plot of CD11b+ and CD29 expression in PEMs from normal and
DA-3 mammary tumor-bearing mice; (C) flow cytometric analysis of
PEMs from control and DA-3 mammary tumor bearers gated on
either CD11blow or CD11bhigh and assessed for the expression of
CD29, N = 8, ∗p ≤ 0.05.
elicited macrophages were used as we wanted to determine
the effect of SEMA7A in circulation on macrophages. Since
RAW 264.7 macrophages treated with rmSEMA7A had increased
expression of CXCL2/MIP-2, we determined if treatment of
N-PEMs with rmSEMA7A had an effect on production of
angiogenic molecule, CXCL2/MIP-2. A considerably (p < 0.05)
enhanced expression of CXCL2/MIP-2 was observed in N-
PEMs pretreated with rmSEMA7A and then stimulated with
LPS (Figure 3E). Given that SEMA7A is known to induce
CXCL2/MIP-2, and PEMs from DA-3 mammary tumor bear-
ers have increased CXCL2/MIP-2 and SEMA7A, we silenced the
SEMA7A gene in DA-3 PEMs using shRNA. Effectiveness of
SEMA7A gene silencing as indicated in the 1st set of bars shows
that SEMA7A gene was significantly (p < 0.001) silenced com-
pared to the scramble control (Figure 3F). SEMA7A gene silenced
DA-3 PEMs expressed significantly less CXCL2/MIP-2 compared
to scramble control as determined by q-PCR (Figure 3F). It is
important to note that our previous studies show that DA-3
cells express CXCL2/MIP-2. It is possible that SEMA7A could
function in an autocrine manner to upregulate the expression
of CXCL2/MIP-2.
DECREASED TUMOR-DERIVED SEMA7A RESULTS IN REDUCED
IN VITRO MACROPHAGE MIGRATION AND CXCL2/MIP-2 PRODUCTION
Holmes et al. demonstrated that SEMA7A is a potent monocyte
chemoattractant with 1000-times greater chemotactic activity
than monocyte chemotactic protein, MCP-1. (Holmes et al.,
2002). We hypothesized that silencing SEMA7A gene in DA-3
mammary tumor cells would result in decreased secretion of
SEMA7A in tumor cell cultures and treatment of macrophages
with this conditioned media would therefore have a nega-
tive influence on their migration. Thus, SEMA7A gene was
silenced in DA-3 mammary tumor cells by shRNA. Western
blotting was performed to test the effectiveness of SEMA7A
gene silencing. Lane 1 indicates DA-3 wild type, lane 2 shows
DA-3 scramble shRNA and lane 3 consists of DA-3 SEMA7A
Frontiers in Physiology | Vascular Physiology February 2014 | Volume 5 | Article 17 | 6
Garcia-Areas et al. Semaphorin7A exerts proangiogenic effect
FIGURE 3 | Increased expression of angiogenic chemokine,
CXCL2/MIP-2 in rmSEMA7A treated RAW264.7 macrophages and
peritoneal elicited macrophages from mammary tumor-bearing mice.
The effect of treatment with rmSEMA7A in RAW264.7 macrophages is
shown in panels (A–C). Expression of CXCL2/MIP-2 at mRNA level (A) and
at protein level determined by ELISA (B) is increased in RAW 264.7
macrophages treated with rmSEMA7A; and (C) effect of treatment with
U0126, a MAPK inhibitor (1μM) on CXCL2/MIP-2 expression by RAW
264.7 macrophages treated with rmSEMA7A. CXCL2/MIP-2 expression is
increased in peritoneal elicited macrophages (PEMs) from DA-3 mammary
tumor bearers compared to N-PEMs: (D) increased mRNA expression of
CXCL2/MIP-2 in DA-3 PEMs compared to PEMs from normal as
determined by qPCR, N = 8; (E) CXCL2/MIP-2 ELISA of normal PEMs
treated with rmSEMA7A and stimulated with LPS; and (F) the effect of
SEMA7A gene knockdown in DA-3 PEMs on mRNA expression of
SEMA7A and CXCL2/MIP-2 as determined by qPCR. In-vitro experiments
are representative of three independent experiments. ∗p ≤ 0.05,
∗∗p ≤ 0.01, ∗∗∗p ≤ 0.001.
shRNA knockdown (Figure 4A, top panel). Integrated intensity
graphs show a 6-fold decrease in SEMA7A expression in DA-
3 SEMA7A shRNA knockdown cells compared to either DA-3
wild type or DA-3 scramble shRNA cells (Figure 4A, bottom
panel). Although DA-3 cells express lower levels of CXCL2/MIP-2
compared to macrophages, silencing the SEMA7A gene also
lead to a decrease in tumor-derived CXCL2/MIP-2. To deter-
mine if SEMA7A plays a role in monocyte migration, a mod-
ified Boyden chamber assay was performed using RAW 264.7
murine macrophages and conditioned media from wild type
DA-3 tumor, DA-3 scramble shRNA, or DA-3 SEMA7A shRNA
knockdown cells as possible chemoattractants. Fewer number
of RAW 264.7 monocytes migrated towards the conditioned
media from SEMA7A silenced DA-3 cells compared to media
from either wild type DA-3 tumor cells or DA-3 cells with
scramble shRNA (Figure 4B). Since we demonstrated that DA-3
mammary tumor cells produce SEMA7A, and that treatment of
macrophages with rmSEMA7A induced the production of proan-
giogenic CXCL2/MIP-2, we hypothesized that silencing SEMA7A
gene in DA-3 mammary tumor cells would have an inhibitory
effect on production of CXCL2/MIP-2 by macrophages treated
with tumor cell supernatants silenced for the SEMA7A gene.
We therefore tested to see if SEMA7A gene silencing in tumor
cells has an effect on CXCL2/MIP-2 chemokine expression. In
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FIGURE 4 | Decreased tumor-derived SEMA7A results in reduced
in vitro macrophage migration and CXCL2/MIP-2 production. (A) Effect
of SEMA7A gene silencing on SEMA7A expression in DA-3 mammary
tumor cells as determined by western blot analysis; (B) migration of Calcein
AM labeled RAW 264.7 macrophages toward cell-free supernatants from
either wild type DA-3 tumor cells, SEMA7A scramble shRNA DA-3 tumor
cells, SEMA7A shRNA knockdown DA-3 cells or serum free media alone.
(C) mRNA expression of CXCL2/MIP-2 on macrophages from normal mice
in vitro treated with conditioned media from either wild type, SEMA7A
scramble or SEMA7A knockdown DA-3 mammary tumor cells. In-vitro
experiments are representative of three independent experiments.
∗∗p ≤ 0.01.
macrophage cultures with conditioned media from SEMA7A
shRNA knockdown DA-3 cells, there was a significant (p < 0.01)
reduction in CXCL2/MIP-2 expression compared to the cultures
with SEMA7A (Figure 4C).
DECREASED TUMOR GROWTH IN MICE BEARING SEMA7A SILENCED
MAMMARY TUMORS
Culturing of RAW 264.7 or thioglycollate elicited macrophages
with rmSEMA7A induced the expression of CXCL2/MIP-2, a
pro-angiogenic chemokine. We have previously shown that mice
bearing either the parental D1-DMBA-3 or DA-3 mammary
tumors exhibit higher levels of pro-angiogenic molecules (Owen
et al., 2011). It is well-established that angiogenesis is required for
invasive tumor growth and that tumors do not grow more than
1mm3 in the absence of angiogenesis (Folkman, 1971). We have
shown in the previous section that SEMA7A induces production
of angiogenic molecules by macrophages. We therefore deter-
mined if implantation of BALB/c mice with SEMA7A knock-
down DA-3 mammary tumors has an inhibitory effect on tumor
growth. To determine the in vivo role of SEMA7A, mice were
implanted with either wild-type DA-3, scramble shRNA DA-3,
or SEMA7A gene knockdown DA-3 (SEMA7A KD) mammary
tumor cells. Mice implanted with SEMA7A KD tumors had sig-
nificantly (p < 0.01) decreased primary tumor volume compared
to the wild type or SEMA7A scramble control DA-3 mammary
tumors (Figure 5A). Since SEMA7A KD tumors had lower tumor
volume, we tested to see if there is decreased angiogenesis in
these mice by use of AngioSense fluorescent probe and CD31
staining by immunohistochemistry. Thus, an AngioSense fluo-
rescent probe was used to determine the extent of angiogenesis
in the tumors by an in vivo imaging system. Shown in the upper
panel are mice bearing wild type DA-3 tumors; the middle panel,
scramble control for shRNA; while the bottom panel shows mice
bearing SEMA7A KD tumors. Significantly (p < 0.01) decreased
angiogenesis was observed in mice bearing the SEMA7A KD
tumors compared to the scramble controls or wild type DA-3
mammary tumors (Figure 5B). We also show the quantifica-
tion results of in vivo imaging indicating a similar trend in
tumor growth. Decrease in angiogenesis in SEMA7A KD tumor
sections was also observed by immunohistochemistry. H&E and
immunohistochemical staining for CD31 highlighted angiogen-
esis in control tumors but minimally in SEMA7A KD tumors
(Figure 5C).
PERITONEAL ELICITED MACROPHAGES FROMMICE BEARING SEMA7A
KD TUMORS PRODUCE DECREASED LEVELS OF ANGIOGENIC
MOLECULES
4–5 weeks post-tumor cell implantation, thioglycollate elicited
macrophages from DA-3 scramble shRNA control or DA-3
SEMA7A shRNA mammary tumor-bearing mice were analyzed
for the production of pro-angiogenic chemokines CXCL2/MIP-2,
CXCL1 and matrix metalloprotease MMP-9. LPS-stimulated
macrophages from mice implanted with SEMA7A gene silenced
DA-3 mammary tumors produce significantly (p < 0.01)
lower amounts of pro-angiogenic molecules compared to
those implanted with SEMA7A scramble control DA-3 tumor
cells. While there were no major differences in secretion of
CXCL2/MIP-2 and CXCL1 in unstimulated macrophages from
either SEMA7A scramble control or SEMA7A silenced mam-
mary tumor-bearing mice, there were significant (p < 0.01)
differences in the production of both these chemokines from
LPS-stimulated (100 ng/ml) cultures (Figures 6A,B). Thus, LPS
stimulated macrophages from scramble control DA-3 mammary
tumors produced ∼25 ng/mL of CXCL2/MIP-2 while those
from SEMA7A silenced tumor bearers produced ∼18 ng/mL
(Figure 6A). Similarly, LPS stimulated macrophages from scram-
ble controls produced ∼24 ng/mL and those from SEMA7A
silenced DA-3 tumor-bearers’ macrophages produced 16.8 ng/mL
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FIGURE 5 | Decreased tumor growth and angiogenesis in mice
bearing SEMA7A silenced mammary tumors. (A) Tumor volume is
decreased in mice bearing SEMA7A shRNA knockdown DA-3 mammary
tumor compared with either wild type or SEMA7A scramble shRNA DA-3
mammary tumors; (B) ventral image of DA-wild type, SEMA7A scramble
shRNA DA-3 or SEMA7A shRNA knockdown DA-3 mammary tumor
bearing mice showing 1 out 20 mice/group; quantification (photons/sec) of
AngioSense specific fluorescent signal indicating decreased angiogenesis
at 21 days post-tumor implantation in the SEMA7A knockdown group,
N = 10 per group, repeated twice ∗∗p ≤ 0.01. (C) H&E and CD31 staining
in tumor sections from DA-3 wild type, scramble shRNA and SEMA7A
shRNA knockdown tumor sections. Significance is indicated ∗p ≥ 0.01.
of CXCL1 (Figure 6B). Interestingly, implantation of SEMA7A
knockdown tumor cells decreased the production of MMP-9
by intraperitoneal macrophages in both unstimulated and
LPS-stimulated cultures (Figure 6C). Furthermore, we assayed
a series of tumorigenesis-related genes by qPCR on peritoneal
macrophages from SEMA7A shRNA KD or shRNA scramble
control DA-3 mammary tumor-bearing mice. PEMs from
SEMA7A KD tumor bearing mice showed a significant reduction
in VEGF-A expression but not VEGF-B expression (Figure 6D).
In contrast, expression of both epidermal growth factor (EGF)
and platelet growth factor (PGF) was significantly reduced in
PEMs from SEMA7A KD tumor bearing mice (Figure 6E).
Interestingly, the levels of serpinf1, a secreted protein that
has both anti-angiogenic and anti-tumorigenic functions, was
significantly increased in PEMs from SEMA7A KD tumor bearers
(Figure 6F).
DISCUSSION
The biological role of SEMA7A in breast cancer progression was
explored in this study. First, we find that SEMA7A is expressed by
mammary tumor cells. Second, we show that SEMA7A expression
is upregulated in macrophages of mammary tumor-bearing mice.
Third, we demonstrate that SEMA7A induces the expression of
proangiogenic molecule CXCL2/MIP-2 in macrophages. Fourth,
we find decreased tumor growth inmice implanted with SEMA7A
shRNA DA-3 mammary tumor cells. Lastly, we find that there is
decreased angiogenesis in mice implanted with SEMA7A knock-
down mammary tumors. These findings suggest that SEMA7A
could have a direct effect on tumor cell growth and macrophage
function. We are the first to show that SEMA7A plays a role in
breast cancer progression.
SEMA7A was first identified in the immune system, as myeloid
and lymphoid lineage cells have been reported to express this
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FIGURE 6 | Macrophages from mice bearing SEMA7A shRNA
knockdown tumors produce decreased levels of angiogenic
molecules. ELISA of peritoneal macrophages from scramble shRNA
DA-3 and SEMA7A shRNA knockdown DA-3 tumor bearers cultured
with and without LPS for protein levels of: (A) CXCL2/MIP-2; (B)
CXCL1; and (C) MMP-9, N = 16. qPCR of peritoneal macrophages
from scramble shRNA DA-3 and SEMA7A shRNA knockdown DA-3
tumor bearers for mRNA expression of: (D) VEGFA and VEGFB; (E)
EGF and PGF; and (F) Serpine 1 and Serpinfl, N = 6, repeated
twice. ∗∗p ≤ 0.01, ∗∗∗p ≤ 0.001.
molecule (Comeau et al., 1998; Lange et al., 1998; Xu et al., 1998).
There are very few reports on SEMA7A expression as it relates
to cancer. We are the first to clearly demonstrate that SEMA7A
is expressed by mammary tumor cells. Formolo et al. identified
SEMA7A as one of the proteins in highly invasive astrocytoma
cell line U87 while the less aggressive cells do not express this
protein (Formolo et al., 2011). Our results parallel with these
results as DA-3 mammary tumor cells had greater intensity in
expression of this SEMA7A compared to the nontumorigenic
mammary EpH4 cells. This raises the possibility that metastatic
tumors express higher levels of SEMA7A. We are actively pur-
suing this in our laboratory by assessing different breast tumor
cell lines with varying levels of metastatic potential for SEMA7A
expression and correlating with aggressive behavior. Interestingly,
while SEMA7A is known to affect monocyte activation in vitro
via β1 integrin–mediated effects (Holmes et al., 2002), the role of
SEMA7A in the activation of tumor cells has not yet been stud-
ied. We found that while PEMs from normal mice express low
levels of SEMA7A, the expression of this protein is increased in
PEMs from tumor bearers. So what induces the expression of
this molecule in macrophages? In a murine fibrosis model, TGF-
β has been reported to induce the expression of SEMA7A in the
murine lung (Kang et al., 2007). We are testing tumor- and/or
host-derived factors in inducing SEMA7A expression in PEMs.
Although the identification of SEMA7A receptors remains
controversial, two potential receptors have been identified, i.e.,
plexin C1 and the β1 subunit of integrin receptor. The bio-
logical activities of SEMA7A in the immune system have only
recently been elucidated. SEMA7A induces the production of
inflammatory cytokines such as IL-6, TNF-α and IL-8 (Suzuki
et al., 2007), an effect that could be mediated through direct inter-
action of GPI-anchored SEMA7A protein with α1β1 integrins on
target cells. Alternatively, SEMA7A could be cleaved by ADAM-
17 and have paracrine effects on other cells. Cell surface bound
semaphorins have been found to be proteolytically cleaved in
order to exert their biological function. For example, in order
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to exert proangiogenic effect, SEMA4D is proteolytically cleaved
by membrane type 1-matrix metalloproteinase, and the result-
ing soluble form acts on endothelial cells to enhance angiogenesis
(Henningsen et al., 2010). SEMA7A is a GPI-anchored protein
that has been found to be cleaved in platelets by ADAM-17
(Fong et al., 2011). We have previously reported increased expres-
sion of ADAM-17 in mammary tumor-bearing mice (Owen
et al., 2003). It is possible that ADAM-17 in the tumor bearers
could affect cleavage of SEMA7A. Biological effects of SEMA7A
have been reported to function through both the soluble and
membrane forms. Soluble SEMA7A has been shown to be an
extremely potent monocyte chemoattaractant (Holmes et al.,
2002) while membrane bound SEMA7A has been reported to
stimulate monocytes and macrophages through α1β1 integrin
and increase production of proinflammatory cytokines including
IL-6 and TNF-α (Suzuki et al., 2007). SEMA7A has been shown
to promote spreading and dendricity in human melanocytes
through its receptor, β1-integrin. In this study, we report that
peritoneal elicited macrophages from mammary tumor-bearing
mice express higher levels of β1 integrins as well as its lig-
and SEMA7A compared to the control mice in tumor bear-
ers’ macrophages, suggesting that SEMA7A could function in
a paracrine manner. In a cancerous system, it is probable that
SEMA7A could mediate its functions through both membrane
and soluble forms.
We have previously shown that macrophages from mammary
tumor-bearing mice produce angiogenic molecules in response
to tumor-derived factors (Libreros et al., 2012). Angiogenesis
plays a crucial role in growth of tumors since solid tumors
cannot grow beyond 1–2mm3 without establishing an ade-
quate blood supply (Folkman, 1971). Using immunohistochem-
istry and an AngioSense probe, an in vivo blood pool vascular
fluorescent imaging agent, we determined the in vivo role of
SEMA7A by comparing angiogenesis in mice bearing scramble
shRNA DA-3 mammary tumors with those bearing SEMA7A
shRNA knockdown DA-3 mammary tumors. Since these stud-
ies showed a significant reduction in tumor volume in SEMA7A
shRNA knockdown DA-3 mammary tumors, we hypothesized
that these mice would produce decreased levels of angiogenic
molecules. It is also possible that although we have knocked
down the gene in the tumor cells, host derived SEMA7A may
contribute toward angiogenesis. Using SEMA7A knockout mice,
we are determining the effects of tumor-derived vs. host-derived
SEMA7A.
Axonal guidance molecule expression is dysregulated in many
types of cancer, including breast cancer, suggesting that they
may be excellent targets for effective therapeutic strategies
(Harburg and Hinck, 2011). In this report we provide novel data
showing that macrophages from SEMA7A shRNA knockdown
mammary tumor bearers have decreased production of angio-
genic chemokines CXCL2/MIP-2 and CXCL1 as well as matrix
degrading enzyme, MMP-9. Although it is known that cytokines
such as TNF-α induce MMP-9 through MAPK pathway (Holvoet
et al., 2003; Moon et al., 2004), there are no studies in liter-
ature describing induction of MMPs by SEMA7A. (Guo and
Giancotti, 2004). We are the first to show a relationship between
MMP-9 and SEMA7A. We speculate that SEMA7A-β1 integrin
ligation may activate MAPK pathway. Activation of MAPK path-
way has been shown to play an important role in tumor invasion
and metastasis via interaction of integrins with specific recep-
tors (Guo and Giancotti, 2004). Further, integrins have been
reported to associate with receptor tyrosine kinases (RTKs) to
activate signaling pathways, including MAPK pathways that are
necessary for tumor invasion and metastasis. We have also shown
that macrophages from SEMA7A shRNA knockdown mammary
tumor bearers have increased levels of serpinf1, a secreted protein
known to have anti-angiogenic and anti-tumorigenic functions
(Filleur et al., 2009). It is possible that SEMA7A could act in
an autocrine manner to upregulate the expression of not only
angiogenicmolecules, but also the integrins to enhancemetastatic
growth. We are now characterizing the effect of SEMA7A on dif-
ferent mammary tumor cells and their ability to migrate and
metastasize. These findings could lead to further studies in the
role of Semaphorin 7A in tumor progression in breast and many
other cancers.
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